Methods for preparation of lipid-encapsulated therapeutic agents

Abstract

Fully lipid-encapsulated therapeutic agent particles of a charged therapeutic agent are prepared by combining a lipid composition containing preformed lipid vesicles, a charged therapeutic agent, and a destabilizing agent to form a mixture of preformed vesicles and therapeutic agent in a destabilizing solvent. The destabilizing solvent is effective to destabilize the membrane of the preformed lipid vesicles without disrupting the vesicles. The resulting mixture is incubated for a period of time sufficient to allow the encapsulation of the therapeutic agent within the preformed lipid vesicles. The destabilizing agent is then removed to yield fully lipid-encapsulated therapeutic agent particles. The preformed lipid vesicles comprise a charged lipid which has a charge which is opposite to the charge of the charged therapeutic agent and a modified lipid having a steric barrier moiety for control of aggregation.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of U.S. patent application Ser. No. 10 / 019,199, filed Dec. 20, 2001, which is a national stage application filed under 35 U.S.C. §371 of International Application No. PCT / CA00 / 00843, accorded an International Filing Date of Jul. 14, 2000, which claims priority to U.S. Provisional Application No. 60 / 143,978, filed Jul. 15, 1999.FIELD OF THE INVENTION [0002] This invention relates to a novel method for making particles of lipid-encapsulated therapeutic agents, and in particular, lipid-encapsulated therapeutic nucleic acid particles which may be useful in antisense therapy or gene therapy. BACKGROUND OF THE INVENTION [0003] The concept of using lipid particles as carriers for therapeutic agents has been considered by numerous people. Formulations have relied on complexation of therapeutic agent to the outside of the lipid particle, or actual entrapment of the therapeutic agent, although the ability to mak...

AI Technical Summary

Benefits of technology

The present invention is about a method for making fully lipid-encapsulated therapeutic agent particles. This is done by combining a lipid composition, a charged therapeutic agent, and a destabilizing agent to form a mixture of preformed vesicles and therapeutic agent in a destabilizing solvent. The destabilizing solvent is effective to destabilize the membrane of the preformed lipid vesicles without disrupting them. The resulting mixture is incubated for a period of time sufficient to allow the encapsulation of the therapeutic agent within the preformed lipid vesicles. The destabilizing agent is then removed to yield fully lipid-encapsulated therapeutic agent particles. The preformed lipid vesicles comprise a charged lipid and a modified lipid for control of aggregation. The method is efficient for large-scale production of lipid particles.

Problems solved by technology

Notwithstanding the many efforts to utilize lipid particles as carriers, there remain problems which may limit actual applications of lipid-entrapped therapeutic agents.

These include low levels of therapeutic agent incorporation on a drug / lipid basis, low efficiency's of capture of the therapeutic agent, and lack of a suitable procedure for larger scale manufacturing of the lipid-encapsulated therapeutic agent particles.

Large scale manufacturing of fully lipid-encapsulated therapeutic agent particles has not been achieved where there is a significant electrostatic interaction between the lipid and the therapeutic agent.

A basic problem is aggregation.

Aggregation normally results when charged lipid is mixed with oppositely charged therapeutic agent, resulting in a solution containing a milky flocculent mass which is not useable for further processing, let alone for therapeutic use.

The aggregation problem has prevented the development of therapeutic compositions which could be of great utility.

Commercial large scale manufacturing of these particles is not efficiently achieved using traditional methods employed in the liposome field.

These problems exist notwithstanding the great deal of art on the manufacturing of liposome / drug formulations that has emerged since the first description of liposome preparation by Bangham, A D. et al.

None of the above noted methods or instruments are suitable for scale up of formulations of charged lipid and oppositely charged therapeutic agents with the excellent pharmaceutical characteristics of Bally et al., supra, and Semple et al., supra.

The manufacturing techniques set out in Bally et al., supra, and Semple et al., supra were developed only for 1-100 ml preparations, and are cumbersome and lead to unsustainable inefficiencies in large scale manufacturing (i.e. at the scale of 20-200 litres).

Images